Testosterone Injectable Market Size

Testosterone Injectable Market size was over USD 2.16 billion in 2024 and is projected to reach USD 3.55 billion by 2037, growing at around 3.9% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of testosterone injectable is assessed at USD 2.3 billion.

The testosterone injectable is one of the most commonly found and popular types of hormone injection therapy all across the world. Owing to increased awareness about the advantages and efficiency of testosterone replacement therapy, the market is anticipated to gain more approval and recognition among patients and consumers.

The high healthcare expenditure with improved healthcare infrastructure is one of the major factors estimated to drive testosterone injectable market expansion during the forecast period. As per the Centers for Medicare & Medicaid Services (CMS), healthcare spending in the United States grew by 9.7% in 2020, reaching a value of USD 4.1 trillion. As a share of the nation’s Gross Domestic Product (GDP), health spending accounted for about 19.7%.

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of testosterone injectable is assessed at USD 2.3 billion.

The testosterone injectable market size was over USD 2.16 billion in 2024 and is projected to reach USD 3.55 billion by 2037, growing at around 3.9% CAGR during the forecast period i.e., between 2025-2037. The market growth is due to rapidly growing geriatric population across the world, and the high prevalence of testosterone deficiency among people worldwide.

Europe industry is estimated to account for largest revenue share by 2037, propelled by presence of various medical centers, and rising government initiatives in the region.

The major players in the market are Bayer AG, Endo Pharmaceuticals Inc., Eli Lilly & Company, Kyowa Kirin International plc, Mylan N.V., Novartis AG

Testosterone Injectable Market Size